| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.0002 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0006 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0006 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.15 | 0.001 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |